GlaxoSmithKline April 25 announced that the Food and Drug Administration has approved Lamictal XR (lamotrigine) extended-release tablets for conversion to monotherapy in patients 13 years and older with partial seizures taking one anti-epileptic drug (AED).
This is a new indication for Lamictal XR, the Research Triangle Park, N.C.-based company said. The drug already is approved as add-on treatment for partial seizures and primary generalized tonic-clonic seizures in patients in this age group (8 PLIR 173, 2/5/10). The safety and effectiveness of Lamictal XR have not been established as initial monotherapy or for simultaneous conversion to monotherapy from two ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.